Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 8Sarcoma 3Lymphoma, B-Cell 3Lymphoma 3Prostatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Inhibition, Psychological 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Colorectal Neoplasms 1Chordoma 1

Interventions

Cyclophosphamide 30N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21Prednisone 20Etoposide 20Vincristine 16Whole-Body Irradiation 15Doxorubicin 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 14romidepsin 13Mycophenolic Acid 12Lenalidomide 12Gemcitabine 12Cyclosporine 10Azacitidine 10Brentuximab Vedotin 9Bortezomib 9Alemtuzumab 8Dexamethasone 7Methotrexate 6Cytarabine 6Busulfan 6Carmustine 5pembrolizumab 4fludarabine 4Vorinostat 4Tacrolimus 4Rituximab 4Melphalan 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Peripheral × tazemetostat × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Ruijin Hospital

Phase 1/2 Not yet recruiting
48 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡